FDA Approves New Drug to Prevent RSV in Babies and Toddlers
Today, the U.S. Food and Drug Administration approved Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants...
Beyfortus® immunization to protect infants from RSV has begun
Oct 28, 2024 · Beyfortus ® is the first immunization designed for all infants to help prevent RSV lower respiratory tract disease through their first RSV season. Beyfortus ® is also indicated for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
There’s a new shot to protect newborns from a serious ... - CNN
Oct 5, 2023 · The new shot, which goes by the brand name Beyfortus, slashed infants’ risk of being hospitalized for RSV by 80% in clinical trials. It promised to be a game-changer for the youngest patients.
Sanofi shipping BEYFORTUS® in US to help protect ... - news…
Sep 16, 2024 · BEYFORTUS is the first and only long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
Press Room - Sanofi US News
Updated as of October 26, 2023. There has been unprecedented demand for Beyfortus™ (nirsevimab-alip). For the first time in history, health care providers are able to help protect an extraordinary number of infants against respiratory syncytial virus (RSV) disease.
RSV shot for infants: Thousands more doses of RSV shot Beyfortus ... - CNN
Nov 16, 2023 · The CDC and FDA are expediting the availability of additional doses of nirsevimab, sold as Beyfortus, the new RSV immunization for infants.
Beyfortus approved in the US for the prevention of RSV lower ...
Jul 17, 2023 · AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second...
More doses of new RSV immunization for babies are on the way ... - CNN
Dec 14, 2023 · CNN — More hard-to-find doses of Beyfortus, the new immunization against respiratory syncytial virus (RSV) for infants, will be available in January, the White House says. The announcement comes...
Press Room - Sanofi US News
Aug 3, 2023 · As a long-acting antibody provided directly to newborns and infants as a single dose, Beyfortus offers rapid protection to help prevent lower respiratory tract disease caused by RSV without requiring activation of the immune system. 7 Beyfortus administration can be timed to the start of the RSV season.
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants
Dec 27, 2023 · The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract infection when...
- Some results have been removed